InflaRx Past Earnings Performance
Past criteria checks 0/6
InflaRx has been growing earnings at an average annual rate of 2.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 93% per year.
Key information
2.3%
Earnings growth rate
22.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 93.0% |
| Return on equity | -87.1% |
| Net Margin | -33,758.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely
Jun 25
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Dec 23InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 17We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Mar 28Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?
Nov 30InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients
Sep 29InflaRx reports Q2 results
Aug 05InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients
Jul 26Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Jul 16InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder
Jul 06InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy
Jun 29Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Apr 01Our First Look At InflaRx
Dec 29Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)
Dec 15InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 27InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
Aug 25InflaRx initiates mid-stage vilobelimab skin cancer trial
Jun 08We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth
May 01Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?
Mar 02We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Jan 08
InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder
Jan 05InflaRx reports Q3 results
Oct 29Revenue & Expenses Breakdown
How InflaRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -57 | 19 | 37 |
| 30 Jun 24 | 0 | -47 | 19 | 33 |
| 31 Mar 24 | 0 | -41 | 18 | 34 |
| 31 Dec 23 | 0 | -43 | 17 | 41 |
| 30 Sep 23 | 0 | -35 | 15 | 41 |
| 30 Jun 23 | 0 | -35 | 14 | 42 |
| 31 Mar 23 | 0 | -27 | 14 | 42 |
| 31 Dec 22 | 0 | -29 | 15 | 38 |
| 30 Sep 22 | 0 | -34 | 15 | 39 |
| 30 Jun 22 | 0 | -38 | 15 | 41 |
| 31 Mar 22 | 0 | -54 | 13 | 41 |
| 31 Dec 21 | 0 | -46 | 12 | 36 |
| 30 Sep 21 | 0 | -42 | 12 | 31 |
| 30 Jun 21 | 0 | -37 | 9 | 27 |
| 31 Mar 21 | 0 | -32 | 9 | 23 |
| 31 Dec 20 | 0 | -34 | 8 | 26 |
| 30 Sep 20 | 0 | -39 | 9 | 31 |
| 30 Jun 20 | 0 | -46 | 10 | 39 |
| 31 Mar 20 | 0 | -52 | 12 | 44 |
| 31 Dec 19 | 0 | -53 | 13 | 45 |
| 30 Sep 19 | 0 | -50 | 13 | 43 |
| 30 Jun 19 | 0 | -42 | 14 | 35 |
| 31 Mar 19 | 0 | -29 | 13 | 27 |
| 31 Dec 18 | 0 | -30 | 13 | 25 |
| 30 Sep 18 | 0 | -31 | 12 | 22 |
| 30 Jun 18 | 0 | -29 | 10 | 19 |
| 31 Mar 18 | 0 | -31 | 8 | 17 |
| 31 Dec 17 | 0 | -24 | 5 | 14 |
| 30 Sep 17 | 0 | -17 | 3 | 11 |
| 30 Jun 17 | 0 | -15 | 3 | 9 |
| 31 Mar 17 | 0 | -12 | 2 | 7 |
| 31 Dec 16 | 0 | -9 | 2 | 5 |
Quality Earnings: IFRX is currently unprofitable.
Growing Profit Margin: IFRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IFRX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare IFRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IFRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: IFRX has a negative Return on Equity (-87.13%), as it is currently unprofitable.